Macquarie Group
BMY.RT

Macquarie Group’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Macquarie Group’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-83,028
Closed -$57K – 2518
2020
Q4 		$57K Buy
83,028
+80,000
+2,642% +$170K ﹤0.01% 2007
2020
Q3 		$187K Sell
3,028
-80,000
-96% -$228K ﹤0.01% 1623
2020
Q2 		$297K Hold
83,028
– – ﹤0.01% 1457
2020
Q1 		$316K Hold
83,028
– – ﹤0.01% 1364
2019
Q4 		$250K Buy
+83,028
New +$216K ﹤0.01% 1544

Other funds holding BMY.RT

JCI
Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return
TNB
Thomasville National Bank Thomasville, Georgia $1.61B AUM 22.15% 1-Year Est. Return
WAM
Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.44B AUM 21.92% 1-Year Est. Return

Macquarie Group's BMY.RT Position: Q1 2021 in Review

Macquarie Group sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 83,028 shares — an estimated $57K sold.

Macquarie Group first reported a position in BMY.RT in Q4 2019 and held it in 5 quarters. The position peaked at $316K in Q1 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

  • Macquarie Group reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
  • Macquarie Group sold 83,028 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $57K.
  • Macquarie Group first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 5 quarters.
  • Macquarie Group's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $316K in Q1 2020.
  • 12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Macquarie Group's 13F filing for Q1 2021, filed 14 May 2021.